Department of Microbial Biotechnology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Campus UAM Cantoblanco, 28049, Madrid, Spain.
Microb Biotechnol. 2017 Sep;10(5):1057-1061. doi: 10.1111/1751-7915.12778. Epub 2017 Jul 11.
The controlled in situ delivery of biologics (e.g. enzymes, cytokines, antibodies) by engineered bacteria of our microbiome will allow the sustainable production of these complex and expensive drugs locally in the human body, overcoming many of the technical and economical barriers currently associated with the global use of these potent medicines. We provide examples showing how engineered bacteria can be effective treatments against multiple pathologies, including autoimmune and inflammatory diseases, metabolic disorders, diabetes, obesity, infectious diseases and cancer, hence contributing to achieve the Global Sustainable Goal 3: ensure healthy lives and promote well-being for all at all ages.
通过我们微生物组中的工程细菌对生物制剂（例如酶、细胞因子、抗体）进行控制的原位递送来实现在人体内局部可持续生产这些复杂和昂贵的药物，克服了目前与这些有效药物在全球使用相关的许多技术和经济障碍。我们提供了一些示例，展示了工程细菌如何成为针对多种病理的有效治疗方法，包括自身免疫和炎症性疾病、代谢紊乱、糖尿病、肥胖症、传染病和癌症，从而有助于实现全球可持续发展目标 3：确保所有人在所有年龄段都享有健康生活和促进福祉。
